Macrophage Assay Testing of 5 Test Molecules on M2 Polarized Cells In Vitro

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95022Q00228 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13'Simplified Acquisition Procedures; and FAR Part 12'Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-06, with effective date 05/01/2022. (iv) The associated NAICS code 541380 Testing Laboratories and the small business size standard is $16.5M. This requirement is full and open with no set-aside restrictions. Description (v) This requirement is for the following commercial services: Macrophage Assay Testing of 5 Test Molecules on M2 Polarized Cells In Vitro (vi) The National Center for Advancing Translational Sciences (NCATS) currently have over 100 compounds that have not been tested to develop a SAR in order to choose the correct analog of a leading compound to proceed as a preclinical candidate for pancreatic cancer. The development of the SAR around these analogs is crucial for the determination of the structural features required to select the proper analog. NCATS requires macrophage assay testing of 5 molecules on M2 polarized cells (derived from monocytes isolated from PBMCs originated from a healthy donor) in vitro. The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) was officially established in fiscal year 2012 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS, one of 27 Institutes and Centers (ICs) at NIH, strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. The Division of Preclinical Innovation (DPI) plans, conducts and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum. Specifically, this division: Plans, conducts and collaborates on research to develop new methods and technologies to enhance preclinical processes. Plans, conducts and collaborates on research to evaluate existing and developing approaches, technologies, and processes in the preclinical spectrum. Supports training programs relevant to preclinical phases of translational science. Allocates DPI resources to preclinical extramural and intramural investigators. Collaborates with other NIH Institutes and Centers and the scientists they support. Consults with stakeholders, including patients, industry and regulators. Currently, NCATS lacks the SAR information that is needed to evaluate the various analogs that have been synthesized. The services herein this Statement of Work (SOW) seeks to address this deficiency by testing all of NCATS current compounds to help pick the proper one as a preclinical candidate. The compound has been shown to be efficacious against cancer in rat and mouse models. NCATS and the National Cancer Institute (NCI) have been working to evaluate and optimize the anticancer properties of its leading compound. Various studies have shown efficacy by NCGC00413972. Thus, NCATS and NCI have the need to optimize and further improve the qualities that were discovered. See attached Statement of Work (SOW) for complete requirement details. (vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated award date is on or before July 1, 2022 and the period of performance is seven (7) weeks from date of purchase order award. Provisions and Clauses (viii) FAR 52.252-1 Solicitation Provisions Incorporated by Reference (Feb 1998) This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es): https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7 System for Award Management (OCT 2018) FAR 52.204-16 Commercial and Government Entity Code Reporting (AUG 2020) FAR 52.212-1 Instructions to Offerors-Commercial Items (NOV 2021) FAR 52.212-3 Offeror Representations and Certifications-Commercial Items (NOV 2021) HHSAR 352.239-73 Electronic and Information Technology Accessibility Notice (December 18, 2015) FAR 52.252-2 Clauses Incorporated by Reference (Feb 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13 System for Award Management Maintenance (OCT 2018) FAR 52.204-18 Commercial and Government Entity Code Maintenance (AUG 2020) FAR 52.212-4 Contract Terms and Conditions--Commercial Items (NOV 2021). HHSAR 352.222-70 Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74 Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their quotation pursuant to FAR 4.2103 Procedures. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (OCT 2020) FAR 52.212-4 Contract Terms and Conditions'Commercial Products and Commercial Services (NOV 2021), Addendum FAR 52.212-5 Contract Terms and Conditions Required To Implement Statutes or Executive Orders'Commercial Products and Commercial Services (MAY 2022) NIH Invoice and Payment Provisions (Vendor has Transitioned to IPP) (Rev. April 21, 2022) or NIH Invoice and Payment Provisions (Vendor has Not Transitioned to IPP) (Rev. April 21, 2022) (either provision will be incorporated at time of PO award depending on whether contractor is IPP enabled) (ix) The Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (NOV 2021), with its offer. If the offeror has completed the current FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (x) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xi) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. Evaluation (xii) The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes: a. Technical capability of the item offered to meet the Government requirement (including offerors experience conducting Macrophage Assay Testing); b. Price; and c. Past performance. Submission Instructions (xiii) Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions must be received by 12 p.m., Eastern Daylight/Standard Time, on Tuesday, May 17, 2022, and reference Solicitation Number 75N95022Q00228. Questions may be submitted electronically to Rieka Plugge, Contracting Officer, at contact@example.gov. All offers/quotations must be received by 4:00 p.m., Eastern Daylight/Standard Time, on Friday, May 20, 2022, and reference Solicitation Number 75N95022Q00228. Responses must be submitted electronically to Rieka Plugge, Contracting Officer, at contact@example.gov. Fax responses will not be accepted.